Want to see VNRX full AI Analyst Report?
VNRX Stock Chart & Stats
$0.18
$0.01(1.52%)
At close: 4:00 PM EST
$0.18
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$1.09 - $16.01
Previous CloseN/A
Volume29.92K
Average Volume (3M)19.46M
Market Cap
$13.61M
Enterprise Value$35.02
Total Cash (Recent Filing)$3.10M
Total Debt (Recent Filing)$11.42M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 19, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.25
Shares Outstanding12,044,339
10 Day Avg. Volume55,156,196
30 Day Avg. Volume19,458,360
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.80
Price to Sales (P/S)15.80
P/FCF Ratio-1.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.00Price Target Upside7677.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$2.27M
Bulls Say, Bears Say
Bulls Say
High-precision Capture-Seq CtDNA TechProprietary Capture-Seq that yields >99% pure tumor-derived DNA and promising early-stage detection positions VolitionRx with a durable technological moat for liquid biopsy applications. Patents, a resubmitted manuscript and strong inbound interest support long-term partner licensing and platform adoption if larger validations follow.
Nu.Q Vet Automation & Feline AssayAutomation partnership with Fujifilm and a high-performing feline assay create a scalable, lower-cost route into veterinary diagnostics. The published-linked $5M milestone and central-lab automation enable recurring reagent and service revenue streams, making the vet channel a durable near-to-medium term commercial opportunity.
Revenue Growth With Solid Gross MarginSustained top-line improvement and a healthy ~60% gross margin indicate product-level economics that can support scalability. If management controls fixed costs and converts validation wins to recurring sales, these underlying unit economics provide a durable pathway to improve operating leverage over the next several quarters.
Bears Say
Severe Cash BurnPersistent large negative operating and free cash flows show the business is not self-funding and must repeatedly access capital. This ongoing burn elevates dilution and execution risk, constraining the company’s ability to scale commercialization or navigate delays in milestones or reimbursements over the next 2–6 months.
Negative Equity And Stressed Balance SheetMaterial negative equity reflects accumulated losses and weak capital buffers, limiting borrowing capacity and increasing counterparty caution. This structural weakness reduces financial flexibility for commercialization investments and raises the probability of further dilutive financings or restrictive covenants in the medium term.
Reliance On Financing And Milestone PaymentsDependence on milestone receipts, ATM proceeds and convertible financings creates structural revenue and funding volatility. Covenant waivers and conversion rights illustrate fragile capital structure: recurring need for external capital and potential dilution weigh on sustainable execution and on-time commercialization over coming quarters.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $1.08 and its highest was $16.01 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $13.61M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Aug 19, 2026 which is in 28 days.
How were VolitionRX’s earnings last quarter?
Currently, no data Available
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.61.
How many shares outstanding does VolitionRX have?
VolitionRX has 12,044,339 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
VNRX Stock 12 Month Forecast
Average Price Target
$14.00
▲(7677.78% Upside)
Technical Analysis
Ownership Overview
9.74% Insiders
1.15% Mutual Funds
― Other Institutional Investors
88.47% Public Companies and
Individual Investors